Fredag 6 Februari | 20:29:33 Europe / Stockholm

Kalender

Est. tid*
2027-02-24 08:00 Bokslutskommuniké 2026
2026-10-28 11:20 Kvartalsrapport 2026-Q3
2026-08-26 11:20 Kvartalsrapport 2026-Q2
2026-05-20 N/A Årsstämma
2026-04-29 11:20 Kvartalsrapport 2026-Q1
2026-02-25 08:00 Bokslutskommuniké 2025
2025-12-04 - Extra Bolagsstämma 2025
2025-10-29 - Kvartalsrapport 2025-Q3
2025-08-27 - Kvartalsrapport 2025-Q2
2025-05-21 - X-dag ordinarie utdelning INIFY 0.00 NOK
2025-05-20 - Årsstämma
2025-04-30 - Kvartalsrapport 2025-Q1
2025-02-26 - Bokslutskommuniké 2024
2024-12-06 - Extra Bolagsstämma 2024
2024-10-23 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning INIFY 0.00 NOK
2024-05-14 - Årsstämma
2024-04-24 - Kvartalsrapport 2024-Q1
2024-02-29 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning INIFY 0.00 NOK
2023-05-16 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-08-30 - Extra Bolagsstämma 2022
2022-08-17 - Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Inify Laboratories tillhandahåller cancerdiagnostik genom laboratorietjänster inom patologi. Bolaget använder ett digitalt, standardiserat arbetsflöde för svarstider och kvalitetssäkring, initialt inom prostata diagnostik. Kunderna består främst utav laboratorier och sjukhus. Inify Laboratories grundades 2022 och har sitt huvudkontor i Stockholm, Sverige.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-12 08:00:04
STOCKHOLM - 12 January 2026 - Reference is made to the stock exchange
announcement made by Inify Laboratories AB (the "Company") on 19 December 2025
regarding the final results of the fully guaranteed private placement (the
"Private Placement"). Further, reference is made to the stock exchange
announcement made by the Company on 17 December 2025 and previous announcements
regarding the fully guaranteed repair issue of 2,304,563 new shares (the "Repair
Issue"). The Repair Issue will be directed pro-rata towards existing
shareholders that did not participate in the Private Placement and who hold less
than 1,000,000 shares in the Company. The offer price per share in the Repair
Issue is NOK 3.50 (the "Offer Price"), equal to the subscription price in the
Private Placement.

The subscription period for the Repair Issue (the "Subscription Period")
commences today, 12 January 2026 at 09:00 (CET) and expires on 26 January 2026
at 16:30 (CET), unless extended at the Company's sole discretion.

The Repair Issue is, subject to applicable securities law, directed pro-rata
towards existing shareholders in the Company as of 16 December 2025 (as
registered in Euronext Securities Oslo (the "VPS") or the share register
maintained by Euroclear Sweden Ab ("Euroclear"), as applicable, on 18 December
2025 (the "Record Date")), who (i) were not eligible to participate in the
Private Placement, and (ii) are not resident in a jurisdiction where such
offering would be unlawful or, would require any prospectus, filing,
registration or similar action ("Eligible Shareholders").

Eligible Shareholders with shares registered with the VPS as of the Record Date
will receive 0.3621 non-tradable subscription rights for each share held by such
Eligible Shareholder in the Company as of the Record Date, subject to certain
limitations based on applicable laws and regulations, that will give right to
subscribe for, and be allocated, one (1) share in the Repair Issue (the "Repair
Issue Shares") at the Offer Price. The number of subscription rights granted to
each Eligible Shareholder will be rounded down to the nearest whole subscription
right. Over-subscription is not allowed. Shareholders with shares registered
directly with Euroclear as of the Record Date will not receive any subscription
rights. Instead, such shareholders will receive an application form which shall
be used to apply for subscription for shares in the Repair Issue.

The following allocation criteria will be used for allotment of Repair Issue
Shares in the Repair Issue:

(i)                  Allocation of the Repair Issue Shares will be made to
subscribers on the basis of granted subscription rights which have been validly
exercised during the Subscription Period. Each subscription right will give the
right to subscribe for and be allocated one (1) Repair Issue Share.

(ii)                If not all subscription rights are validly exercised in the
Subscription Period, allotment shall be made to Monsun AS and Auris AS (the
"Guarantors"), companies controlled by the same owners as the Company's two
largest shareholders Gallivant S.à r.l. and Tauri AS, respectively, in
proportion to the size of their respective share of the guarantee commitment,
and to the extent that this cannot be done, by drawing lots.

Only Eligible Shareholders may participate in the Repair Issue. Subscription
without subscription rights is not permitted (save for subscriptions by the
Guarantors in accordance with the allocation principles set out above).
Allocation of fewer Repair Issue Shares than subscribed for by a subscriber will
not impact the subscriber's obligation to pay for the number of Repair Issue
Shares allocated. The Company will not allocate fractional Repair Issue Shares.
The Company reserves the right to round off, reject or reduce any subscription
for Repair Issue Shares.

Notifications of allocation of Repair Issue Shares and the corresponding
subscription amount to be paid by each subscriber are expected to be distributed
by SB1 Markets AS (the "Manager") on or around 28 January 2026. Subscribers who
have access to investor services through their VPS account manager is expected
to be able to check the number of Repair Issue Shares allocated to them from
around 15:00 CET on 28 January 2026. Subscribers who do not have access to
investor services through their VPS account manager is expected to be able to
contact the Manager from 15:00 CET on 28 January 2026 to obtain information
about the number of Repair Issue Shares allocated to them.

The subscription rights must be used to subscribe for shares in the Repair Issue
prior to expiry of the Subscription Period. Subscription rights that are not
used to subscribe for shares in the Repair Issue before the expiry of the
Subscription Period will have no value and will lapse without compensation to
the holder.

The date for payment of the Repair Issue is expected to be on or about 25 March
2026 (the "Payment Date"). The new shares in the Repair Issue are expected to be
delivered on or about 30 March 2026, subject to turnaround time for registration
of the share capital increases relating to the Repair Issue with the Swedish
Companies Registration Office ("SCRO"). The shares allocated in the Repair Issue
will be tradable on Euronext Growth Oslo when the new shares have been
registered with the SCRO and registered by Euroclear Sweden and VPS,
respectively, expected on or about 30 March 2026.

Subscription for new shares in the Repair Issue is made by submitting a
correctly completed subscription form to SB1 Markets AS, the manager in the
Repair Issue (the "Manager"), per e-mail or ordinary post as described in the
subscription form. The subscription form will be available at
http://www.sb1markets.no/transaksjoner/ and will also be sent by post to all
Eligible Shareholders.  Subscribers who are resident in Norway and have a
Norwegian national identification number are encouraged to subscribe for new
shares in the Repair Issue through the VPS online subscription system (or by
following the link on http://www.sb1markets.no/transaksjoner/, which will
redirect the subscriber to the VPS online subscription system).

Company update - webinar on 23 January 2026 at 12:30 (CET)

The Company will host a webinar where the Company's CEO, Fredrik Palm, will
provide a company update and also answer any questions regarding the Repair
Issue and the Private Placement. The webinar will be held on 23 January 2026 at
12:30 (CET). For registration, please send an e-mail to
corporateaccess@sb1markets.no.

Advisors

SB1 Markets AS ("SB1 Markets") has been appointed as financial advisor in
connection with the Private Placement and the Repair Issue. Schjødt law firm
acts as legal counsel to the Company.

For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)

###

This information is subject to the disclosure requirements pursuant to section 5
-12 the Norwegian Securities Trading Act.

Important information

The release, announcement or distribution of this press release may, in certain
jurisdictions, be subject to restrictions. The recipients of this press release
in jurisdictions where this press release has been published or distributed
shall inform themselves of and follow such restrictions. The recipient of this
press release is responsible for using this press release, and the information
contained herein, in accordance with applicable rules in each jurisdiction. The
information in this press release does not contain or constitute an offer to
acquire, subscribe or otherwise trade in shares, subscription rights or other
securities in the Company in any jurisdiction.

This press release does not identify or suggest, or purport to identify or
suggest, the risks (direct or indirect) that may be associated with an
investment in new shares. Any investment decision in connection with the Private
Placement and the Repair Issue must be made on the basis of all publicly
available information relating to the Company and the Company's shares. Such
information has not been independently verified by SB1 Markets. The information
contained in this announcement is for background purposes only and does not
purport to be full or complete. No reliance may be placed for any purpose on the
information contained in this announcement or its accuracy or completeness. SB1
Markets is acting for the Company in connection with the transaction and no one
else and will not be responsible to anyone other than the Company for providing
the protections afforded to its clients nor for giving advice in relation to the
transaction or any other matter referred to herein.

This press release does not constitute a recommendation concerning any
investor's option with respect to the Private Placement and the Repair Issue.
Each investor or prospective investor should conduct his, her or its own
investigation, analysis and evaluation of the business and data described in
this announcement and publicly available information. The price and value of
securities can go down as well as up. Past performance is not a guide to future
performance.

The information contained in this press release is not intended for, and must
not be accessed by, or distributed or disseminated, directly or indirectly, in
whole or in part, to persons resident or physically present in the United States
of America (including its territories and possessions, any state of the United
States and the District of Columbia) (the "United States"), Australia, Canada,
Hong Kong, Japan, New Zealand, Singapore, South Africa, United Kingdom or any
other jurisdiction where such action is wholly or partially subject to legal
restrictions, or would require additional prospectuses, registration or other
measures than those required by Norwegian law. The information in the press
release does not constitute any offer regarding subscription rights, paid
subscribed shares or shares in the Company ("Securities") to any person in said
jurisdictions. The information in the press release may not be forwarded or
reproduced in such a manner that contravenes such restrictions or gives cause to
such requirements.

No securities have been or will be registered under the United States Securities
Act of 1933, as amended (the "Securities Act") or the securities legislation of
any state or other jurisdiction in the United States and may not be offered,
subscribed for, exercised, used, pledged, sold, resold, granted, delivered or
otherwise transferred, directly or indirectly, in or into the United States
except pursuant to an applicable exemption from, or in a transaction not subject
to, the registration requirements under the Securities Act and in compliance
with the securities legislation in the relevant state or any other jurisdiction
of the United States.

Within the European Economic Area ("EEA"), no public offering of Securities is
made in other countries than Sweden or Norway. In other member states of the EU,
such an offering of Securities may only be made in accordance with the
Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation"). In other
member states of the EEA which have implemented the Prospectus Regulation in its
national legislation, any offer of Securities may only be made in accordance
with an applicable exemption in the Prospectus Regulation and/or in accordance
with an applicable exemption under a relevant national implementation measure.

In the United Kingdom, this document and any other materials in relation to the
securities described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this document relates is
available only to, and will be engaged in only with, "qualified investors" who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of "investment professionals" in
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order")